Proactive Investors - Run By Investors For Investors

Harvest One Cannabis posts record revenue, enjoying boost from Dream Water subsidiary

Highlights of its fiscal first quarter include agreements to supply adult-use cannabis to four provinces: British Columbia, Ontario, Manitoba and Saskatchewan
A greenhouse with marijuana plants
Cannabis company Harvest One says it maintained a strong balance sheet with a cash balance of C$48.3 million

Harvest One Cannabis Inc (CVE:HVT) (OTCMKTS:HRVOF) said it posted record quarterly revenue driven by its Dream Water subsidiary’s sales and bulk sales to other licensed producers.

For its fiscal first quarter ended September 30, the Vancouver-based company said Thursday that its revenue surged to C$1.68 million, almost 10 times the C$174,544 reported a year earlier. Another factor in the boost was an initial recreational-cannabis sale to the province of British Columbia.

READ: MMJ Group Holdings completes sale of unit to Harvest One Cannabis for C$8 million

Highlights included agreements to supply adult-use cannabis to four provinces: Ontario, Manitoba and Saskatchewan, as well as British Columbia.

“I am proud to say Harvest One has executed on our roll-out strategy, meeting all provincial obligations and establishing the basis for successful long-term relationships with both public and private retailers,” said Grant Froese, who assumed the role of CEO in July. “The work we are doing now lays the foundation for a landmark year in 2019, when cannabis companies will be judged on execution and financial performance.”

The company also acquired a 19.99% interest in a British Columbia-based luxury retail group known as Burb Cannabis Corp. Burb expects to open eight to 10 stores in BC in 2019. The investment falls within the allowable maximum investment of 20% established by the British Columbia government, according to Harvest One.

Harvest One added that it maintained a strong balance sheet with a cash balance of C$48.3 million. Its comprehensive loss widened to C$5.8 million, or C$0.03 per share, from C$1.9 million, or C$0.02 per share.

The company cited favorable results in Phase 2 clinical trials of its Satipharm capsules for the treatment of pediatric epilepsy. The median seizure reduction was 82% in the 12-week treatment period. These results were recently presented at the Epilepsy Society of Australia Conference.

Harvest One recently closed its acquisition of Phytotech Therapeutics, adding research capabilities to support product development for Satipharm.

Shares of Harvest One slipped C$0.01 to C$0.42 in Thursday's Canadian trading. They were down US$0.01 to US$0.31 on the OTC market.

Contact Dennis Fitzgerald at [email protected]

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full HVT profile View Profile

Harvest One Cannabis Inc Timeline

May 02 2019

Related Articles

cannabis plant
December 14 2018
The Vancouver-based cannabis group services medical and recreational cannabis markets in Canada and internationally
Sydney Harbour Bridge
January 22 2019
A phase I study in Australia is evaluating a cannabis spray therapeutic in cancer patients.
A visual representation of a drug candidate working in a dog
January 28 2019
The company has reaffirmed its upcoming milestones as it confirmed December quarter achievements.
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use